BTG 271

Drug Profile

BTG 271

Latest Information Update: 26 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Savient Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 26 Mar 2008 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 04 Jul 2003 Bio-Technology General is now called Savient Pharmaceuticals
  • 30 Jul 2002 Preclinical development for Acute myeloid leukaemia in USA (Unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top